1. Discovery of an Oleanolic Acid/Hederagenin-Nitric Oxide Donor Hybrid as an EGFR Tyrosine Kinase Inhibitor for Non-Small-Cell Lung Cancer
- Author
-
Yung Yi Cheng, Susan L. Morris-Natschke, Huaqing Duan, Xiao-Hang Tong, Shi-Lin Yang, Zhong Chen, Yan-Li Liu, Yong Ling, Pan-Chyr Yang, Masuo Goto, Kuo-Yen Huang, and Kuo Hsiung Lee
- Subjects
Lung Neoplasms ,Pharmaceutical Science ,Antineoplastic Agents ,Nitric Oxide ,01 natural sciences ,Analytical Chemistry ,Nitric oxide ,chemistry.chemical_compound ,T790M ,Carcinoma, Non-Small-Cell Lung ,Cell Line, Tumor ,Drug Discovery ,Humans ,Nitric Oxide Donors ,Kinase activity ,Oleanolic Acid ,Oleanolic acid ,Protein Kinase Inhibitors ,Pharmacology ,A549 cell ,010405 organic chemistry ,Kinase ,Organic Chemistry ,Gefitinib ,Antineoplastic Agents, Phytogenic ,respiratory tract diseases ,0104 chemical sciences ,ErbB Receptors ,010404 medicinal & biomolecular chemistry ,Hederagenin ,Complementary and alternative medicine ,chemistry ,Cell culture ,A549 Cells ,Drug Resistance, Neoplasm ,Drug Design ,Mutation ,Cancer research ,Molecular Medicine - Abstract
Natural triterpenoids, such as oleanolic acid (OA) and hederagenin, display anti-lung cancer effects, and nitric oxide (NO) is associated with some oncogenic signaling pathways. Accordingly, 17 OA/hederagenin-NO donor hybrids were designed, synthesized, and evaluated against tumor cells. The most potent compound, 13, significantly inhibited the proliferation of five tumor cell lines (IC50 4.6-5.2 μM), while hederagenin inhibited the growth of only A549 tumor cells (IC50 > 10 μM). Furthermore, compound 13 showed stronger inhibitory effects on EGFR-LTC kinase activity (IC50 0.01 μM) than hederagenin (IC50 > 20 μM) and inhibited the proliferation of gefitinib-resistant H1975 (IC50 8.1 μM) and osimertinib-resistant H1975-LTC (IC50 7.6 μM) non-small-cell lung cancer (NSCLC) cells. Moreover, compound 13 produced the most NO in H1975 tumor cells, which indicated that NO may play a synergistic role. Collectively, compound 13, a novel hederagenin-NO donor hybrid with a different chemical structure from those of the current FDA-approved EGFR-targeted anti-NSCLC drugs, may be a promising lead compound for the treatment of NSCLC expressing gefitinib-resistant EGFR with a T790 M mutation or osimertinib-resistant EGFR-LTC with an L858R/T790M/C797S mutation. This work should shed light on the discovery of new anti-NSCLC drugs targeting EGFR from natural products.
- Published
- 2019